
    
      Official Title - Randomized, Open-Label, Single Dose, 3 Period, Crossover Evaluation of the
      Relative Bioavailability of Two Experimental Fixed-Dose Combination Tablet Formulations of
      Dolutegravir 50 mg/Abacavir 600 mg/Lamivudine 300 mg Compared to Co administered Dolutegravir
      50 mg and EPZICOMâ„¢ (Abacavir 600 mg/Lamivudine 300 mg) Tablets in Healthy Adult Subjects.

      ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of
      updating systems to reflect the change in sponsorship
    
  